肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

乳腺癌新辅助化疗的研究进展

2011-11-13 MedSci原创 MedSci原创

乳腺癌新辅助化疗
关注

乳腺癌新辅助化疗的研究进展

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=37347, encodeId=4ab33e34784, content=What a plauesre to find someone who thinks through the issues, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=muhammad, createdTime=Sun Sep 27 07:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678454, encodeId=242a16e8454fd, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Thu May 17 09:10:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380327, encodeId=132e138032e12, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Nov 14 15:10:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2015-09-27 muhammad

    What a plauesre to find someone who thinks through the issues

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=37347, encodeId=4ab33e34784, content=What a plauesre to find someone who thinks through the issues, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=muhammad, createdTime=Sun Sep 27 07:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678454, encodeId=242a16e8454fd, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Thu May 17 09:10:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380327, encodeId=132e138032e12, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Nov 14 15:10:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2012-05-17 charl1234576

    #新辅助#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=37347, encodeId=4ab33e34784, content=What a plauesre to find someone who thinks through the issues, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=muhammad, createdTime=Sun Sep 27 07:00:00 CST 2015, time=2015-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1678454, encodeId=242a16e8454fd, content=<a href='/topic/show?id=110c5869153' target=_blank style='color:#2F92EE;'>#新辅助#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58691, encryptionId=110c5869153, topicName=新辅助)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=941f27706894, createdName=charl1234576, createdTime=Thu May 17 09:10:00 CST 2012, time=2012-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1380327, encodeId=132e138032e12, content=<a href='/topic/show?id=9281e34519b' target=_blank style='color:#2F92EE;'>#研究进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73451, encryptionId=9281e34519b, topicName=研究进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f13d475, createdName=mashirong, createdTime=Mon Nov 14 15:10:00 CST 2011, time=2011-11-14, status=1, ipAttribution=)]
    2011-11-14 mashirong

    #研究进展#

    0

相关资讯

MammaPrint的背景、临床运用及展望

MammaPrint的背景、临床运用及展望

蒽环类药物心脏毒性保护剂临床应用的热点问题

蒽环类药物心脏毒性保护剂临床应用的热点问题

回顾分析十年间东北地区乳腺癌诊治模式的演变

回顾分析十年间东北地区乳腺癌诊治模式的演变

前哨淋巴结阳性乳腺癌新辅助化疗后淋巴引流区辅助放疗的意义

前哨淋巴结阳性乳腺癌新辅助化疗后淋巴引流区辅助放疗的意义

Herceptin 在HER2+乳腺癌的辅助和新辅助治疗

Herceptin 在HER2+乳腺癌的辅助和新辅助治疗

乳腺癌化疗进展

乳腺癌化疗进展